About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 129 record(s)
Req # A-2021-001972
Adverse Drug Reactions (ADRs). Report numbers: E2B_02678266, E2B_02806936, E2B_02628528, E2B_00013898.Organization: Health Canada
November 2022
Req # A-2021-002001
Adverse Drug Reactions (ADRs) for IRBESARTAN, INFLUENZA VACCINE TRIVALENT. Report numbers: E2B_04136141, 000935967.Organization: Health Canada
November 2022
Req # A-2021-002002
Adverse Drug Reactions (ADRs) for Escitalopram. Report numbers: E2B_03749624, 935127, 939513, 939934, E2B_03794891, 939914, 940767, 939356. ADRs for Citalopram. Report numbers: 936397, 935476, E2B_03759699, E2B_03763412, 939955. ADR for Vortioxetine. Report number: 938352. ADRs for Flupentixol. Report numbers: 945665, E2B_03897835.Organization: Health Canada
November 2022
Req # A-2021-002150
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, ALIROCUMAB, CABAZITAXEL, ENOXAPARIN SODIUM, FUROSEMIDE. Report numbers: E2B_04758298, E2B_04689981, 000975004, 000974526, E2B_04699189, E2B_04797737, E2B_04690770, 000969438, 000977216, E2B_04802742.Organization: Health Canada
November 2022
Req # A-2022-000168
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-103404-679.Organization: Health Canada
November 2022
Req # A-2022-000279
Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: E2B_05094789, E2B_05136554, E2B_05130529, E2B_05179616, E2B_05138467, E2B_05112451, E2B_05186024, E2B_05162489, E2B_05186355, E2B_05160299.Organization: Health Canada
November 2022
Req # A-2022-000306
Adverse Drug Reactions (ADRs). Report numbers: E2B_05138972, 000986032, 982822, 000984656, E2B_05184620, E2B_05167224, E2B_05173074, E2B_05138899.Organization: Health Canada
November 2022
Req # A-2022-000345
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-120716-336.Organization: Health Canada
November 2022
Req # A-2022-000399
Adverse Drug Reaction (ADR). Report number: E2B_05272389.Organization: Health Canada
November 2022
Req # A-2022-000482
Adverse Drug Reactions (ADRs) for ISENTRESS. Report numbers: E2B_02232811, E2B_00102288, E2B_00207546, E2B_00208393, E2B_00210233, E2B_00102274, E2B_00702948, E2B_02754434, E2B_02998603, E2B_03004950.Organization: Health Canada
November 2022